Our US-Based Support team is available to help. Contact Us Now
Phone: 800-441-1045 | Email: support@kidneyhood.org
Albutrix was developed to address limitations that previous-generation keto acid analogs had not solved. Most alternatives were formulated decades ago, before current understanding of calcium supplementation risks, magnesium's role in CKD survival outcomes, and the importance of glycemic safety for the large population of diabetic kidney patients.
Every differentiation below is based on formulation science, current guideline compliance, or documented clinical outcomes — not marketing claims.
✔ Albutrix incorporates patent-pending magnesium keto analogs and specialized magnesium/calcium blends, designed to align with clinical guidance aimed at reducing health risks for stage 3 and 4 kidney patients.
✔ Albutrix delivers the lowest nitrogen content of any protein food or supplement designed for kidney patients.
✔ Albutrix (S3 & S4) contains the lowest supplemental calcium profile, helping patients seamlessly manage their mineral intake compared to other keto acid analog protein options.
✔ Albutrix also acts as a phosphorus binder.
✔ Albutrix is a specialized keto acid analog designed as part of an integrated strategy to help lower the workload on your kidneys.
✔ Albutrix offers flexible formulations tailored to your current blood tests, ensuring you can choose the right keto acid analog or protein food for your specific needs.
✔ Albutrix is low-glycemic and diabetic-friendly, specifically formulated without the high-glycemic sugars or starches, like maltodextrin, often found as primary ingredients in other options.
✔ Albutrix aligns closely with major nutritional standards when combined with the Stopping Kidney Disease Diet and Microtrix, reflecting guidelines from the National Kidney Foundation, the Academy of Nutrition and Dietetics, and clinical guidance from over 20 countries.
✔ Albutrix provides full label transparency by explicitly listing nitrogen, calcium, magnesium, and dietary protein equivalents, giving patients and caregivers the precise data needed to plan diets accurately.
✔ Albutrix allows patients to consume more calories and dietary protein each day with the same or lower nitrogen load as other whey, plant protein and amino acid blended supplements.
The Clinical Standard We Hold Ourselves to
The Kidneyhood program has been studied in human CKD patients using the same clinical endpoints the FDA requires for kidney disease drug approval — eGFR, BUN, and creatinine. The pilot study used informed consent, HIPAA-compliant data collection, and standard statistical methodology. A statistically significant dose-response relationship between achieved BUN level and eGFR improvement (p = 0.002) was identified.
We recognize that a new integrated approach must earn its evidence. We welcome that standard.
US Patent 11,253,496 | EU Patent 3,799,724 | New clinical studies underway 2026 Manufactured in FDA-registered US facilities | Lot-tested before every release
US-BASED SUPPORT
Still Have Questions?
FDA-REGISTERED & USA MADE